Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Breast Cancer
100%
Metastatic Breast Cancer
52%
Hormone Therapy
42%
Estrogen Receptor
28%
Triple Negative Breast Cancer
27%
Genetics
24%
Circulating Tumor DNA
19%
Neoplasm
19%
Estrogen
19%
Tumor
19%
Hormone Receptor
18%
Aromatase Inhibitor
16%
Fulvestrant
16%
Diseases
15%
Cyclin-Dependent Kinase 4
15%
Clinical Trial
15%
Biological Marker
14%
Targeted Therapy
13%
Malignant Neoplasm
13%
CDK4/6 Inhibitor
12%
Estrogen Receptor Positive Breast Cancer
12%
Progression Free Survival
11%
Overall Survival
11%
Chemotherapy
10%
Postmenopause
10%
Palbociclib
10%
Neoadjuvant Chemotherapy
9%
Recurrent Disease
9%
Xenograft
8%
Phase II Trials
8%
Circulating Tumor Cell
8%
Gamma Urogastrone
8%
Hazard Ratio
8%
Neratinib
7%
Anastrozole
7%
Epidermal Growth Factor Receptor 2
6%
Combination Therapy
6%
Epidermal Growth Factor Receptor
6%
Neoadjuvant Therapy
6%
Progesterone Receptor
6%
Protein Kinase B
6%
Receptor Expression
6%
Carboplatin
6%
Letrozole
6%
Tumor Progression
5%
Race Difference
5%
Phosphoinositide 3-Kinase
5%
Cancer Mortality
5%
Oncology
5%
Treatment Response
5%
Keyphrases
Breast Cancer
60%
Triple-negative Breast Cancer
44%
Metastatic Breast Cancer
36%
Tumor
27%
Cyclin-dependent Kinase 4 (CDK4)
25%
Circulating Tumor DNA (ctDNA)
23%
Endocrine Therapy
22%
Human Epidermal Growth Factor Receptor 2 (HER2)
22%
ER+ Breast Cancer
18%
Aromatase Inhibitors
18%
Advanced Breast Cancer
17%
Neoadjuvant Endocrine Therapy
17%
Estrogen Receptor 1 (ESR1)
16%
Estrogen Receptor
16%
Fulvestrant
14%
Palbociclib
14%
Cyclin-dependent Kinase 6 (CDK6)
13%
Phase II Trial
13%
Estrogen
13%
Phase I Study
12%
Postmenopausal Women
12%
Estrogen Receptor-positive
12%
Patient-derived Xenograft
12%
Endocrine Resistance
10%
Chemotherapy
10%
Targeted Therapy
10%
Neoadjuvant
10%
95% Confidence Interval
10%
Breast Cancer Patients
10%
Neoadjuvant Chemotherapy
9%
Progression-free Survival
9%
Selective Estrogen Receptor Modulators
9%
HER2-negative Breast Cancer
9%
Patient Outcomes
9%
Carboplatin
9%
ESR1 mutation
9%
Clinical Trials
9%
Overall Survival
9%
Pathological Complete Response
9%
Hormone Receptor-positive
9%
Cyclin-dependent Kinase 4/6 Inhibitors
9%
Resistance Mechanism
8%
Hormone Receptor-positive Metastatic Breast Cancer
8%
Neratinib
8%
Hazard Ratio
8%
Combination Therapy
8%
Paclitaxel
8%
Trastuzumab
7%
Mammalian Target of Rapamycin (mTOR)
7%
Bortezomib
7%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
66%
Metastatic Breast Cancer
42%
Estrogen Receptor
31%
Neoplasm
25%
Endocrine Therapy
25%
Fulvestrant
23%
Triple Negative Breast Cancer
19%
Hormone Receptor
18%
Cyclin Dependent Kinase 4
18%
Aromatase Inhibitor
17%
Diseases
17%
Malignant Neoplasm
17%
Estrogen
16%
Clinical Trial
15%
Chemotherapy Regimens
13%
Progression Free Survival
12%
Biological Marker
11%
Estrogen Receptor Positive Breast Cancer
11%
Gamma Urogastrone
11%
Neratinib
11%
Phase II Trials
10%
Protein Kinase B
10%
Carboplatin
9%
Tumor Growth
9%
Epidermal Growth Factor Receptor
8%
Palbociclib
8%
Epidermal Growth Factor Receptor 2
8%
Anastrozole
8%
Trastuzumab
8%
Pharmacokinetics
7%
Bortezomib
7%
Paclitaxel
7%
Abemaciclib
6%
Phosphatidylinositol 3 Kinase
6%
Maximum Tolerated Dose
6%
Temsirolimus
6%
Irinotecan
6%
Doxorubicin
6%
Adverse Event
6%
Monotherapy
6%
Solid Malignant Neoplasm
6%
Disease Exacerbation
5%
Cyclin Dependent Kinase 6
5%